Periodic Reporting for period 1 - microMESH (Preclinical validation and market analysis of a microMESH implant for brain cancer eradication)

Glioblastoma (GBM) is the most aggressive and common malignant brain tumor, with an incidence of about 5 cases per 100,000 people annually. Despite aggressive treatment, including surgery, radiation, and chemotherapy, the median survival remains well below 2 years, with a...